1. Home
  2. YQ vs NSPR Comparison

YQ vs NSPR Comparison

Compare YQ & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YQ

17 Education & Technology Group Inc.

N/A

Current Price

$3.05

Market Cap

34.8M

Sector

Real Estate

ML Signal

N/A

Logo InspireMD Inc.

NSPR

InspireMD Inc.

N/A

Current Price

$0.45

Market Cap

38.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YQ
NSPR
Founded
2012
2005
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.8M
38.9M
IPO Year
2020
2009

Fundamental Metrics

Financial Performance
Metric
YQ
NSPR
Price
$3.05
$0.45
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $3.33
AVG Volume (30 Days)
4.3K
★ 225.0K
Earning Date
12-08-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,310,000.00
Revenue This Year
$274.52
$9.14
Revenue Next Year
$29.79
$105.44
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.68
$0.43
52 Week High
$5.30
$2.40

Technical Indicators

Market Signals
Indicator
YQ
NSPR
Relative Strength Index (RSI) 33.44 30.09
Support Level $1.85 $0.43
Resistance Level $2.81 $0.72
Average True Range (ATR) 0.16 0.05
MACD -0.09 0.01
Stochastic Oscillator 0.01 16.44

Price Performance

Historical Comparison
YQ
NSPR

About YQ 17 Education & Technology Group Inc.

17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Share on Social Networks: